Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Kohlmann

Showing results (61-70 of 102) with videos related to

Pageof 11
Sort By:
Genes, Chromosomes & Cancer|January 24, 2013
The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALLVera Grossmann, Claudia Haferlach, Sandra Weissmann, et al.
British Journal of Haematology|March 26, 2013
CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosisVera Grossmann, Claudia Haferlach, Niroshan Nadarajah, et al.
Oncogene|July 25, 2003
Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPalpha DNA binding via leucine zipper domain interactionJanki Rangatia, Rajani K Vangala, Sheo M Singh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2010
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1Alexander Kohlmann, Vera Grossmann, Hans-Ulrich Klein, et al.
Haematologica|June 27, 2012
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 casesSusanne Schnittger, Ulrike Bacher, Tamara Alpermann, et al.
Biomed Research International|April 3, 2014
TET2 overexpression in chronic lymphocytic leukemia is unrelated to the presence of TET2 variationsMaría Hernández-Sánchez, Ana Eugenia Rodríguez, Alexander Kohlmann, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURAHelen Brown, Johan Vansteenkiste, Kazuhiko Nakagawa, et al.
Plos One|May 5, 2017
Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patientsElza C de Bruin, Jessica L Whiteley, Claire Corcoran, et al.
Blood|December 24, 2013
Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patientsNicolas Rapin, Frederik Otzen Bagger, Johan Jendholm, et al.
Oncogene|August 29, 2003
The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent mannerAnnika Elsässer, Michael Franzen, Alexander Kohlmann, et al.
Pageof 11

Showing results (61-70 of 102) with videos related to

Sort By:
Pageof 11
Genes, Chromosomes & Cancer|January 24, 2013
The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALLVera Grossmann, Claudia Haferlach, Sandra Weissmann, et al.
British Journal of Haematology|March 26, 2013
CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosisVera Grossmann, Claudia Haferlach, Niroshan Nadarajah, et al.
Oncogene|July 25, 2003
Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPalpha DNA binding via leucine zipper domain interactionJanki Rangatia, Rajani K Vangala, Sheo M Singh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2010
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1Alexander Kohlmann, Vera Grossmann, Hans-Ulrich Klein, et al.
Haematologica|June 27, 2012
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 casesSusanne Schnittger, Ulrike Bacher, Tamara Alpermann, et al.
Biomed Research International|April 3, 2014
TET2 overexpression in chronic lymphocytic leukemia is unrelated to the presence of TET2 variationsMaría Hernández-Sánchez, Ana Eugenia Rodríguez, Alexander Kohlmann, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURAHelen Brown, Johan Vansteenkiste, Kazuhiko Nakagawa, et al.
Plos One|May 5, 2017
Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patientsElza C de Bruin, Jessica L Whiteley, Claire Corcoran, et al.
Blood|December 24, 2013
Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patientsNicolas Rapin, Frederik Otzen Bagger, Johan Jendholm, et al.
Oncogene|August 29, 2003
The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent mannerAnnika Elsässer, Michael Franzen, Alexander Kohlmann, et al.
Pageof 11